-
Mashup Score: 4
Dr. Maddocks hopes that current trials will help us “spring forward” into a chemotherapy-free approach to treating MCL.
Source: bloodcancerstoday.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 11Persistent Cancer Cells: The Deadly Survivors - PubMed - 22 day(s) ago
Persistent cancer cells are the discrete and usually undetected cells that survive cancer drug treatment and constitute a major cause of treatment failure. These cells are characterized by their slow proliferation, highly flexible energy consumption, adaptation to their microenvironment, and phenoty …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Assessing Efficacy of Acalabrutinib-Rituximab Followed by Chemo and ASCT for Patients With Treatment-Naive MCL - 23 day(s) ago
Eliza A Hawkes, MD, shares findings from the phase 2 WAMM trial, which assessed the use of acalabrutinib-rituximab followed by chemotherapy and autologous stem cell transplantation among young and fit patients with treatment-naive MCL.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 66
Pirtobrutinib and venetoclax combination overcomes resistance to targeted and chimeric antigen receptor T-cell therapy in aggressive mantle cell lymphoma
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1China’s National Medical Products Administration Accepts sBLA for Relma-Cel Injection | Blood Cancers Today - 2 month(s) ago
In a clinical trial, relma-cel demonstrated a three-month ORR of 81.36% in patients with relapsed or refractory mantle cell lymphoma (MCL).
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 2
Liso-cel received regulatory acceptances from the US FDA and the Ministry of Health, Labour and Welfare in Japan for FL.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 0Bispecific Lentiviral Anti-CD20/Anti-CD19 CAR T-Cells for R/R MCL - 3 month(s) ago
During the 2023 ASH Annual Meeting in San Diego, Nirav N Shah, MD, discussed the efficacy of dual-targeted lentiviral anti-CD20/anti-CD19 (LV20.19) CAR T-cells with an adaptive manufacturing process among patients with relapsed/refractory mantle cell lymphoma.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
Kami Maddocks, MD, reviews new possibilities and the latest advances in the treatment of patients with mantle cell lymphoma with Jia Ruan, MD, PhD, and Krish Patel, MD.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
Investigators report high response rates with pirtobrutinib in those with mantle cell lymphoma and high-risk disease features in the phase 1/2 BRUIN trial.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1
An abstract is unavailable.
Source: journals.lww.comCategories: General Medicine News, Onc News and JournalsTweet
🌷 In this associate editor's message, @kmaddmd, of @OSUCCC_James, discusses advancements in the treatment approach to #MCL and hopes that current trials will help us “spring forward” into a chemotherapy-free approach. 📖 Read the full message here: https://t.co/64NDdcb03x https://t.co/5euTDI9sMS